Hostname: page-component-f554764f5-nwwvg Total loading time: 0 Render date: 2025-04-23T00:38:49.377Z Has data issue: false hasContentIssue false
  • English
  • Français

Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants

Published online by Cambridge University Press:  07 November 2014

Stephen M. Stahl  and
Angela Felker
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Trends in Psychopharmacology
Information
CNS Spectrums , Volume 13 , Issue 10 , October 2008 , pp. 855 - 871
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1.Amsterdam, JD. Monoamine oxidase inhibitor therapy in severe and resistant depression. Psychiatr Ann. 2006;36:607–613.Google Scholar
2.Stahl, SM. Stahl's Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008.Google Scholar
3.Zisook, S. A clinical overview of monoamine oxidase inhibitors. Psychosomatics. 1985;26:240-246, 251.Google Scholar
4.Krishnan, KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68(suppl 8):35–41.Google Scholar
5.Tollefson, GD. Monoamine oxidase inhibitors: a review. J Clin Psychiatry. 1983;44:280–288.Google Scholar
6.Versiani, M, Nardi, AE, Mundim, FD, et al.The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol. 1996;11 (suppl 3):83–88.CrossRefGoogle ScholarPubMed
7.Cole, JO, Bodkin, JA. MAO inhibitors: an option worth trying in treatment-resistant cases. Current Psychiatry. 2002;1:40–47.Google Scholar
8.Rascol, O. Rasagiline in the pharmacotherapy of Parkinson's disease—a review. Expert Opin Pharmacother. 2005;6:2061–2075.Google Scholar
9.Cascade, EF, Kalali, AH, Preskom, SH. Emsam: The first year. Psychiatry. 2007:19–21.Google Scholar
10.Stahl, SM. Essential Psychopharmacology: The Prescribers Guide. New York, NY: Cambridge University Press; 2006.Google Scholar
11.Schatzberg, AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry. 2007;68(suppl 8):26–34.Google Scholar
12.Jacob, CP, Muller, J, Schmidt, M, et al.Cluster B personality disorders are associated with allelic variation of monoamine oxidase A activity. Neuropsychopharmacoloy. 2005;30:1711–1718.Google Scholar
13.Ballas, CA, Evans, DL, Dinges, DF. Psychostimulants in psychiatry: amphetamine, methylphenidate and modafinil. In: Textbook of Psychopharmacology. Schatzberg, A, Nemeroff, C, eds. Washington, DC: American Psychiatric Publishing, Inc.; 2004:671–684.Google Scholar
14.Kupiec, TC, Chaturvedi, AK. Stereochemical determination of selegiline metabolites in postmortem biological specimens. J Forensic Sci. 1999;44:222–226.Google Scholar
15.Shin, H. Metabolism of selegiline in humans: identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 1997;25:657–662.Google Scholar
16.Magyar, MK, Szatmary, I, Szebeni, G, Lengyel, J. Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. J Neural Transm Suppl. 2007;72:165–173.Google Scholar
17.Feinberg, SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry. 2004;65:1520–1524.Google Scholar
18.Feighner, JP, Herbstein, J, Damlouji, N. Combined MAOI, TCA and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry. 1985;46:206–209.Google Scholar
19.Fawcett, J, Kravitz, HM, Zajecka, JM, Schaff, MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991;11:127–132.CrossRefGoogle ScholarPubMed
20.Schoepp, DD, Azzarro, AJ. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. J Neurochem. 1981;36:2025–2031.Google Scholar
21.Fowler, CJ, Tipton, KF. On the substrate specificities of the two forms of monoamine oxidase. J Pharm Pharmacol. 1984;36:111–115.Google Scholar
22.Chen, K, Holschneider, DP, Wu, W, Rebrin, I, Shih, JC. A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior. Biol Chem. 2004;279:39645–39652.Google Scholar
23.Da Prada, M, Kettler, R, Keller, HH, Burkard, WP, Muggli-Maniglio, D, Haefely, WE. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Pharmacol Exp Ther. 1989;248:400–414.Google Scholar
24.Lotufo-Neto, F, Trivedi, M, Thase, ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20:226–247.Google Scholar
25.Patkar, AA, Pae, CU, Masand, PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006;11:363–373.Google Scholar
26.Mendis, N, Pare, CM, Sandier, M, Glover, V, Stern, GM. Is the failure of (-) deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology. 1981;73:87–90.Google Scholar
27.Mann, JJ, Frances, A, Kaplan, RD, Kocsis, J, Peselow, ED, Gershon, S. The relative efficacy of I-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. J Clin Psychopharmacol. 1982;2:54–57.Google Scholar
28.Sunderland, T, Cohen, RM, Molchan, S, et al.High-dose selegiline in treatment resistant older depressive patients. Arch Gen Psychiatry. 1994;51:607–615.Google Scholar
29.Birkmeyer, W. Implications of combined treatment with “Madopar” and L-deprenyl in Parkinson's disease: a long-term study. Lancet. 1977;26:439–443.Google Scholar
30.Postma, JU, Vranesic, D. Moclobemide in the treatment of depression in demented geriatric patients. Acta Ther. 1985;11:249–252.Google Scholar
31.Nutt, D, Demyttenaere, K, Janka, Z, et al.The other face of depression, reduced positive affect: The role of catecholamines in causation and cure. Psychopharmacol. 2007;21:461–471.Google Scholar
32.McCabe, B, Tsuang, MT. Dietary consideration in MAO inhibitor regimens. J Clin Psychiatry. 1982;43:178–181.Google ScholarPubMed
33.Gardner, DM, Shulman, KI, Walker, SE, Tailor, SA. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57:99–104.Google Scholar
34.Da Prada, M, Zurcher, G, Wuthrich, I, Haefely, WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988;26:31–56.Google Scholar
35.Sweet, RA, Brown, EJ, Heimberg, RG, et al.Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? J Clin Psychiatry. 1995;56:196–201.Google Scholar
36.Shulman, KI, Walker, SE, MacKenzie, S, Knowles, S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9:397–402.Google Scholar
37.Shulman, KI, Walker, SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry. 1999;60:191–193.Google Scholar
38.Shulman, KI, Walker, SE. Psychiatr Ann. 2001;31:378–384.Google Scholar
39.Knoll, J, Magyar, K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972;5:393–408.Google Scholar
40.Wecker, L, Copeland, JS, Pacheco, MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003:541099–541104.Google Scholar
41.Mawhinney, M, Cole, D, Azzaro, AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003;55:27–34.Google Scholar
42.Keller, HH, Kettler, R, Burkard, WP, et al. Preclinical characteristics of moclobemide, a short-acting MAO-A inhibitor with low liability to enhance the tyramine pressor effect. Abstract presented at: annual meeting of the Collegium Internationale Neuro-Psychopharmacologicum. Session 3102: Antidepressants and MAO inhibitors. August 16, 1988; Munich, GermanyGoogle Scholar
43.Priest, RG. Recent clinical development with reversible and selective amine oxidase inhibitors: a valuable addition to the armamentarium. J Clin Psychopharmacol. 1995, 15(suppl 2):1–3.Google Scholar
44.Stabl, M, Biziere, K, Schmid-Burgk, W, Amrein, R. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states. J Neural Transm Suppl. 1989;28:77–89.Google Scholar
45.Angst, J, Amrein, R, Stabl, M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol. 1995;15(4 suppl 2):16S–23S.Google Scholar
46.Amsterdam, JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208–214.Google Scholar
47.Robinson, DS. Transdermal selegiline: A new-generation MAOI. Primary Psychiatry. 2006;13:33–35.Google Scholar
48.Zsilia, G, Foldi, P, Held, G, Szekely, AM, Knoll, J. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission: comparison with clorgyline. Pol J Pharmacol Pharm. 1986;38:57–67.Google Scholar
49.Bodkin, JA, Siris, SG, Bermanzohn, PC, Hennen, J, Cole, JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 2005;162:388–390.Google Scholar
50.Shimazu, S, Minami, A, Kusumoto, H, Yoneda, F. Antidepressant-like effects of selegiline in the forced swim test. Eur Neuropsychopharmacol. 2005;15:563–571.Google Scholar
51.Feiger, AD, Rickels, K, Rynn, MA, Zimbroff, DL, Robinson, DS. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67:1354–1361.Google Scholar
52.Blob, LF, Sharoky, M, Campbell, BJ, et al.Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. CNS Spectr. 2007;12:25–34.Google Scholar
53.Sternbach, H. Serotonin syndrome: how to avoid, identify, and treat dangerous drug interactions. Current Psychiatry. 2003;2:15–23.Google Scholar
54.Gillman, PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry. 2006;59:1046–1051.Google Scholar
55.Lawrence, KR, Adra, M, Gillman, PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42:1578–1583.Google Scholar
56.Gillman, PK. Understanding toxidromes: serotonin toxicity. J Clin Psychopharmacol. 2005;25:625–626.Google Scholar
57.Ginsberg, DL. Psychopharmacology Reviews: serotonin syndrome due to interaction between antibiotic linezolidand norfluoxetine. Primary Psychiatry. 2005;12:27–28.Google Scholar
58.Berlanga, C, Ortega-Soto, HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord. 1995;34:187–192.Google Scholar
59.Houtsmuller, EJ, Notes, LD, Newton, T, et al.Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology. 2004;172:31–40.Google Scholar
60.Gillman, PK. Extracting value from case reports: lessons from serotonin toxicity. Anaesthesia. 2006;61:419–422.Google Scholar
61.Dvir, Y, Smallwood, P. Serotonin syndrome: a complex but easily avoidable condition. Gen Hosp Psychiatry. 2008;30:284–287.Google Scholar
62.Boyer, EW, Shannon, M. The serotonin syndrome. N Engl J Med. 2005;352:1112–1120.Google Scholar
63.Gillman, PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151:737–748.Google Scholar
64.Sabelli, HC. Rapid treatment of depression with selegiline-phenylalanine combination. J Clin Psychiatry. 1991;52:137.Google Scholar
65.Taylor, BP, Quitkin, FM, McGrath, PJ, Stewart, JW. Do antihypertensives make tranylcypromine safer? Three case reports. J Clin Psychiatry. 2005;66:657–658.Google Scholar
66.Gillman, PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95:434–441.Google Scholar
67.Joffe, RT, Bakish, D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry. 1994;55:24–25.Google Scholar
68.Fuller, RW, Snoddy, HD. Inhibition of serotonin uptake and the toxic interaction between meperidine and monoamine oxidase inhibitors. Toxicol Appl Pharmacol. 1975;32:129–134.Google Scholar